UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

	OnKure Therapeutics, Inc.
	(Name of Issuer)
	Class A Common Stock, par value \$0.0001 per share
	(Title of Class of Securities)
	68277Q105
	(CUSIP Number)
	October 4, 2024
	(Date of Event Which Requires Filing of this Statement)
Check	the appropriate box to designate the rule pursuant to which this Schedule is filed:
	Rule 13d-1(b)
\times	Rule 13d-1(c)
	Rule 13d-1(d)
	remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for absequent amendment containing information which would alter the disclosures provided in a prior cover page.
	aformation required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act 84 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the).

CUSIP No. 68277Q105

1.	Names of Reporting Persons					
	Samsara BioCapital, L.P.					
2.	Check	the Ap	ppropriate Box if a Member of a Group (See Instructions)			
	(a) 🗆	(b) 🗵	$\mathbb{E}(1)$			
3.	SEC U	se On	ly			
4.	4. Citizenship or Place of Organization					
	Delawa	ire				
		5.	Sole Voting Power			
Numi	ber of		0			
Share		6.	Shared Voting Power			
Bene: Own	ficially		824,155 (2)			
Each		7.	Sole Dispositive Power			
Repo			0			
reiso	Person With		Shared Dispositive Power			
			824,155 (2)			
9.	9. Aggregate Amount Beneficially Owned by Each Reporting Person					
	824,155 (2)					
10.	10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □					
11.	11. Percent of Class Represented by Amount in Row (9)					
	6.5% (3)					
12.			orting Person (See Instructions)			
	PN					

- (1) This Schedule 13G is filed by Samsara BioCapital, L.P. ("Samsara LP"), Samsara BioCapital GP, LLC ("Samsara GP") and Dr. Srinivas Akkaraju ("Dr. Akkaraju") (and together with Samsara LP, Samsara GP, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Dr. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
- (3) This percentage is calculated based on 12,652,811 shares of Class A Common Stock outstanding as of October 4, 2024, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 8, 2024.

CUSIP N	682	77010	15
COSH IN	0. 002	// / / 1	"

1.	Names of Reporting Persons				
	Samsara BioCapital GP, LLC				
2.	Check	the Ap	propriate Box if a Member of a Group (See Instructions)		
	(a) 🗆	• •			
3.	SEC U	se On	ly		
4.	Citizen	ship o	r Place of Organization		
	Delawa	re			
		5.	Sole Voting Power		
Numl	ber of		0		
Share	es	6.	Shared Voting Power		
Bene:	ficially		824,155 (2)		
Each	,	7.	Sole Dispositive Power		
Repo	rting n With		0		
1 0150	71 ***1611	8.	Shared Dispositive Power		
			824,155 (2)		
9.	9. Aggregate Amount Beneficially Owned by Each Reporting Person				
	824,155 (2)				
10.	0. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □				
11.	11. Percent of Class Represented by Amount in Row (9)				
	6.5% (3)				
12.	Type of	Repo	orting Person (See Instructions)		
	00				

- (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Dr. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
- (3) This percentage is calculated based on 12,652,811 shares of Class A Common Stock outstanding as of October 4, 2024, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 8, 2024.

CI	ICID	No	6827	701	04
·ι	JOH	INU.	004/	/01	· U~

			V			
1.	Names of Reporting Persons					
	Srinivas Akkaraju					
2.	Check	the Ap	opropriate Box if a Member of a Group (See Instructions)			
	(a) 🗆	(b) 🗵	$\mathbb{P}(1)$			
3.	SEC U	se On	ly			
4.	. Citizenship or Place of Organization					
	United	States				
		5.	Sole Voting Power			
Numl	her of		0			
Share	es	6.	Shared Voting Power			
	ficially		824,155 (2)			
	Owned by Each Reporting Person With		Sole Dispositive Power			
			0			
1 6180	II VVILII	8.	Shared Dispositive Power			
			824,155 (2)			
9.	Aggregate Amount Beneficially Owned by Each Reporting Person					
	824,155 (2)					
10.	10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □					
11.	11. Percent of Class Represented by Amount in Row (9)					
	6.5% (3)					
12.		-	orting Person (See Instructions)			
	IN					

- (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Dr. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
- (3) This percentage is calculated based on 12,652,811 shares of Class A Common Stock outstanding as of October 4, 2024, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 8, 2024.

Item 1.

- (a) Name of Issuer OnKure Therapeutics, Inc.
- (b) Address of Issuer's Principal Executive Offices 6707 Winchester Circle, Suite 400, Boulder, CO 80301

Item 2.

(a) Name of Person Filing

Samsara BioCapital, L.P. ("Samsara LP")

Samsara BioCapital GP, LLC ("Samsara GP")

Srinivas Akkaraju ("Dr. Akkaraju")

(b) Address of Principal Business Office or, if none, Residence

c/o Samsara BioCapital, LLC

628 Middlefield Road

Palo Alto, CA 94301

(c) Citizenship

Entities:

Samsara LP

Delaware

Samsara GP

Delaware

Individuals:

Dr. Akkaraju - United States

(d) Title of Class of Securities

Class A Common Stock, par value \$0.0001 per share ("Class A Common Stock")

(e) CUSIP Number 68277Q105

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership

The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of October 11, 2024:

		Sole	Shared	Sole	Shared	Beneficial	
Reporting	Shares Held	Voting	Voting	Dispositive	Dispositive	Ownership	Percentage
Persons	Directly	Power	Power (1)	Power	Power (1)	(1)	of Class (2)
Samsara LP	824,155	0	824,155	0	824,155	824,155	6.5%
Samsara GP	0	0	824,155	0	824,155	824,155	6.5%
Dr. Akkaraju	0	0	824,155	0	824,155	824,155	6.5%

- (1) These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Dr. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
- (2) This percentage is calculated based on 12,652,811 shares of Class A Common Stock outstanding as of October 4, 2024, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 8, 2024.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: October 11, 2024
Samsara BioCapital, L.P.
By: Samsara BioCapital GP, LLC its General Partner
By: /s/ Srinivas Akkaraju Name: Srinivas Akkaraju Title: Managing Member
Samsara BioCapital GP, LLC
By: /s/ Srinivas Akkaraju Name: Srinivas Akkaraju Title: Managing Member
/s/ Srinivas Akkaraju
Srinivas Akkaraju ATTENTION
Intentional misstatements or emissions of fact constitute Federal Criminal Violations (See 18 II S.C. 1001)

Exhibit(s):

A Joint Filing Agreement

EXHIBIT A

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Class A Common Stock of OnKure Therapeutics, Inc. is filed on behalf of each of us.

Dated: October 11, 2024

Samsara BioCapital, L.P.

By: Samsara BioCapital GP, LLC its General Partner

By: /s/ Srinivas Akkaraju
Name: Srinivas Akkaraju
Title: Managing Member

Samsara BioCapital GP, LLC

By: /s/ Srinivas Akkaraju
Name: Srinivas Akkaraju
Title: Managing Member

/s/ Srinivas Akkaraju Srinivas Akkaraju